G1 Therapeutics

$18.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.82 (-4.20%) As of 1:22 PM EST today

Why Robinhood?

You can buy or sell GTHX and other stocks, options, and ETFs commission-free!

About GTHX

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC. The listed name for GTHX is G1 Therapeutics, Inc. Common Stock.

CEO
Mark A. Velleca
Employees
104
Headquarters
Research Triangle Park, North Carolina
Founded
2008
Market Cap
708.22M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.39M
High Today
$19.73
Low Today
$18.45
Open Price
$19.43
Volume
875.38K
52 Week High
$31.38
52 Week Low
$8.80

Collections

GTHX News

BloombergNov 30

Tesla’s S&P Debut Will Come All at Once, Rippling Across Markets

TipRanks Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-ter
BenzingaNov 30

Return On Capital Employed Overview: G1 Therapeutics

During Q3, G1 Therapeutics (NASDAQ: GTHX) brought in sales totaling $26.60 million. However, earnings decreased 68.38%, resulting in a loss of $9.74 million. G1

GTHX Earnings

-$0.98
-$0.65
-$0.33
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like